We are driven by science and believe innovation requires strong collaboration to execute our vision.
Built on Nobel-Winning Science
We honor Dr. Fred Ramsdell, SonomaBio co-founder, for receiving the 2025 Nobel Prize in Physiology or Medicine for his discovery of regulatory T cells (Tregs) and the FOXP3 gene—breakthroughs that revolutionized immune regulation and inspired our mission.
Restoring balance is the key to unlocking cures.
We are developing cell therapies designed to restore balance to the immune system with the potential to cure autoimmune and inflammatory diseases.
Our focus brings hope.
We are focused on improving the lives of patients with autoimmune and inflammatory diseases.
We are pioneers in regulatory T cell (Treg) biology and cell therapy.
We are building upon decades of research by our founders.
Our approach is being validated in the clinic
We are evaluating our lead regulatory T cell (Treg) program in clinical trials.
Firmly grounded in science and collaboration.
Restoring immune system balance using engineered regulatory T cells (Tregs)
SonomaBio pursues a strategy to treat—and potentially cure—autoimmune and inflammatory diseases.
Our approach is being validated in the clinic.
We are evaluating our lead Treg program in clinical trials.
Our focus brings hope.
We are focused on curing autoimmune and inflammatory diseases and radically improving the lives of patients with autoimmune and inflammatory diseases.
Press Releases
SonomaBio In The News
Careers at SonomaBio
We unite our people under a shared commitment to innovation, collaboration, diversity and a sense of belonging, and finding cures for patients.